Osuga, Yutaka
Seki, Yoshifumi
Tanimoto, Masataka
Kusumoto, Takeru
Kudou, Kentarou
Terakawa, Naoki
Clinical trials referenced in this document:
Documents that mention this clinical trial
Relugolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, in women with endometriosis-associated pain: phase 2 safety and efficacy 24-week results
https://doi.org/10.1186/s12905-021-01393-3
Article History
Received: 26 February 2021
Accepted: 9 June 2021
First Online: 21 June 2021
Declarations
:
: The study was conducted in accordance with the principles of the Declaration of Helsinki, the International Council for Harmonisation Guideline for Good Clinical Practice, and all applicable laws and regulations. All patients provided written informed consent before enrollment in this extension study. Ethics approval for the study, including the protocol and informed consent form, was obtained from the Institutional Review Board (IRB) for each study site: Chayamachi Ladies Clinic IRB, Osaka Clinical Research Collaborative Network IRB, Jinsenkai Hanna Hospital IRB, Doujin Kinenkai Meiwa Hospital IRB, Shintokai Yokohama Minoru Clinic IRB, International University of Health and Welfare, Kouhoukai Group Kyushu District Clinical Trial IRB, Hakataeki-Higashi Clinic IRB, Chiba Kaihin Municipal Hospital IRB, Eiyukai Yasuda Hospital IRB, Jikeikai Shinsuma General Hospital IRB, Sapporo Medical Association IRB, Bokai Tenshi Hospital IRB, Suita Municipal Hospital IRB, Kansai Rosai Hospital IRB, Saiseikai Suita Hospital IRB, Yuwakai Kimura Hospital IRB, Yokohama Sakae Kyowai Hospital IRB, Nippon Koukan Hospital IRB, Koujinkai Sapporo Dermatology Clinic IRB, Tokushima Red Cross Hospital IRB, Yamate Dermatological Clinic IRB, Tokushukai Group IRB, Seiwakai Shouda Hospital IRB, Kumamoto City Hospital IRB, Toyama Prefectural Central Hospital IRB, Japanese Red Cross Nagoya Daiichi Hospital IRB, Higashiyama Shinagawa Clinic IRB, National Hospital Organization Central Review Board, Seikoukai Kusatsu General Hospital IRB, Japanese Red Cross Kyoto Daini Hospital IRB, Ehime Rosai Hospital IRB, NTT Medical Center Tokyo IRB, Chiba Rosai Hospital IRB, Nara Prefectural General Medical Center IRB, Fuyo Association Seirei Numazu Hospital IRB, Kagoshima City Hospital IRB, Iizuka Hospital IRB, Fukui General Hospital IRB, Osaka City University Hospital IRB, Oita Prefectural Hospital IRB, Chiyukai Fukuoka Shin Mizumaki Hospital IRB, Northern Kyushu Saiseikai Central IRB, Funabashi Municipal Medical Center IRB, Kagawa Rosai Hospital IRB, Japanese Red Cross Takayama Hospital IRB, Hamanomachi Hospital IRB, Tazuke Kofukai Medical Research Institute, Kitano Hospital IRB, Wakokai Kawasaki Rinko General Hospital IRB, Hiroshima Prefectural Hospital IRB, Fukui Prefectural Hospital IRB, Ogikubo Hospital IRB, Yuasa Houonkai Central IRB, Jizankai Tsuboi Hospital IRB, Tokyo Women's Medical University IRB, Kochi Medical School Hospital IRB, Okayama City Hospital IRB, Ikeda City Hospital IRB, Kawanishi City Hospital IRB, Hiratsuka Kyosai Hospital IRB, Japanese Red Cross Kumamoto Hospital IRB, Satokai Yuge Neuropsychiatric Hospital IRB, Kurashiki Medical Center IRB, Ekihigashi Hihuka Clinic IRB, Marunouchi Hospital IRB, Mizuo Clinic IRB, Ishikawa Prefectural Central Hospital IRB, Osaka Police Hospital IRB, Teine Keijinkai Hospital IRB, Shinagawa East One Medical Clinic IRB, Showa University Fujigaoka Hospital IRB, Yaizu City Hospital IRB, Osaka Central Hospital IRB, Enshu Hospital IRB, Nagano Prefectural Susaka Hospital IRB, Ogori Daiichi General Hospital IRB, Minami Sakai Hospital IRB, and Nagano Municipal Hospital Clinical Research (Clinical Trial) IRB.
: Not applicable.
: KK, MT, and TK are employees, and YS was a past employee, of Takeda Pharmaceutical Company Limited. NT and YO have no competing interests to declare.